| Size | Price | Stock | Qty |
|---|---|---|---|
| 200mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 2g |
|
||
| 5g | |||
| 10g | |||
| Other Sizes |
| Targets |
Aminoglycoside
Kanamycin B binds to the bacterial 16S rRNA subunit, specifically targeting the A-site of the ribosome. This binding interferes with the decoding site, inhibiting translocation and causing misreading of the genetic code, which ultimately leads to the inhibition of protein synthesis. The compound's antibacterial activity is primarily directed against Gram-negative bacteria. |
|---|---|
| ln Vitro |
Bekanamycin, also known as Kanamycin B, is typically extracted from the broth of S. kanamyceticus and is a precursor for semisynthetic antibiotics like Arbekacin and Dibekacin[2].
While bekanamycin (also known as Kanamycin B) has no discernible effect on the configuration of the extracellularly recorded presynaptic action potential, it does, in a concentration-dependent manner, reduce the quantal content of the end-plate potentials reversibly. Bekanamycin causes evoked transmitter release to decrease, but this can be countered by raising the concentration of calcium outside the body or by using medications like aminopyridines, which significantly increase the release of transmitters from motor nerve terminals. Strong inhibitory effects of bekanamycin on transmitter release are likely caused by disruption of the calcium influx that takes place during motor nerve terminal depolarization[3]. In vitro, Kanamycin B displays antibacterial efficacy against Gram-negative bacteria. It is used as a selection agent in molecular biology and as a research tool to study ribosomal function and antibiotic resistance mechanisms. The compound's activity is typically assessed using minimum inhibitory concentration (MIC) assays against various bacterial strains. |
| ln Vivo |
In vivo, Kanamycin B has been used to treat infections caused by Gram-positive and Gram-negative bacteria and Mycobacterium tuberculosis. It is administered via intramuscular injection for systemic infections. However, its clinical use has been largely superseded by other aminoglycosides due to toxicity concerns. It is primarily used as a research tool.
|
| Enzyme Assay |
In vitro binding assays for Kanamycin B involve measuring its affinity for the bacterial ribosome, specifically the 16S rRNA. Techniques such as surface plasmon resonance (SPR) or fluorescence polarization can be used to quantify the binding interaction. Alternatively, cell-free translation assays can be employed to measure the inhibition of protein synthesis, which provides a functional readout of the compound's activity.
|
| Cell Assay |
In vitro cellular assays for Kanamycin B typically involve determining the minimum inhibitory concentration (MIC) against a panel of bacterial strains using the broth microdilution method. The compound's ability to inhibit bacterial growth is assessed by culturing bacteria in the presence of serial dilutions of the antibiotic and measuring optical density. Time-kill kinetics assays can also be performed to evaluate its bactericidal activity.
|
| Animal Protocol |
In vivo animal models for Kanamycin B typically involve infecting mice or rats with pathogenic bacteria and then administering the antibiotic via intramuscular or subcutaneous injection to assess its therapeutic efficacy. The primary endpoints are survival rate, reduction in bacterial load in target organs (e.g., lungs, spleen), and prevention of sepsis.
|
| ADME/Pharmacokinetics |
Kanamycin B has a molecular weight of 483.51 g/mol and a molecular formula of C18H37N5O10. It is a water-soluble compound. The compound is typically stored as a powder at room temperature or -20°C for long-term stability. It is also known as Aminodeoxykanamycin, Bekanamycin, and Nebramycin V.
|
| Toxicity/Toxicokinetics |
Kanamycin B is an aminoglycoside antibiotic with a toxicity profile similar to other drugs in its class. The primary toxicities associated with aminoglycosides are nephrotoxicity (kidney damage) and ototoxicity (hearing loss and balance problems). These effects are dose-dependent and can be irreversible. The compound should be handled with care in laboratory settings.
|
| References |
|
| Additional Infomation |
Kanamycin B is a member of the kanamycin family and is the conjugating base of kanamycin B(5+). Bekanamycin has been reported in both honeybees (Apis cerana) and Streptomyces kanamyceticus, with relevant data available. Bekanamycin is an aminoglycoside antibiotic derived from Streptomyces kanamyceticus and possesses antibacterial activity. Bekanamycin irreversibly binds to the bacterial 30S ribosomal subunit. Specifically, the antibiotic is located between the 16S rRNA and S12 protein within the 30S subunit. This leads to interference with the translation initiation complex, mRNA misreading, thereby inhibiting protein synthesis and ultimately producing a bactericidal effect.
Kanamycin B (CAS# 4696-76-8) is an aminoglycoside antibiotic produced by Streptomyces kanamyceticus. It binds to the bacterial 16S rRNA subunit, inhibiting protein synthesis. It is used in research to study bacterial protein synthesis and as a selection agent. The compound is for research use only and is not for human therapeutic use. |
| Molecular Formula |
C18H37N5O10
|
|---|---|
| Molecular Weight |
483.51
|
| Exact Mass |
483.254
|
| Elemental Analysis |
C, 44.71; H, 7.71; N, 14.48; O, 33.09
|
| CAS # |
4696-76-8
|
| Related CAS # |
4696-76-8;29701-07-3 (sulfate);
|
| PubChem CID |
439318
|
| Appearance |
White to off-white solid powder
|
| Density |
1.6±0.1 g/cm3
|
| Boiling Point |
807.7±65.0 °C at 760 mmHg
|
| Melting Point |
178-182° (dec)
|
| Flash Point |
442.3±34.3 °C
|
| Vapour Pressure |
0.0±6.5 mmHg at 25°C
|
| Index of Refraction |
1.668
|
| LogP |
-2.93
|
| Hydrogen Bond Donor Count |
11
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
33
|
| Complexity |
639
|
| Defined Atom Stereocenter Count |
15
|
| SMILES |
O([C@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])N([H])[H])O1)O[H])O[H])N([H])[H])[C@]1([H])[C@]([H])(C([H])([H])[C@]([H])([C@@]([H])([C@@]1([H])O[H])O[C@]1([H])[C@@]([H])([C@]([H])([C@@]([H])([C@@]([H])(C([H])([H])O[H])O1)O[H])N([H])[H])O[H])N([H])[H])N([H])[H]
|
| InChi Key |
SKKLOUVUUNMCJE-FQSMHNGLSA-N
|
| InChi Code |
InChI=1S/C18H37N5O10/c19-2-6-11(26)12(27)9(23)17(30-6)32-15-4(20)1-5(21)16(14(15)29)33-18-13(28)8(22)10(25)7(3-24)31-18/h4-18,24-29H,1-3,19-23H2/t4-,5+,6+,7+,8-,9+,10+,11+,12+,13+,14-,15+,16-,17+,18+/m0/s1
|
| Chemical Name |
(2R,3S,4R,5R,6R)-5-amino-2-(aminomethyl)-6-(((1R,2S,3S,4R,6S)-4,6-diamino-3-(((2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2-hydroxycyclohexyl)oxy)tetrahydro-2H-pyran-3,4-diol
|
| Synonyms |
Bekanamycin; NK-1006; NK1006; NK 1006; Nebramycin V
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 100 mg/mL (~206.82 mM)
DMSO : ~1 mg/mL (~2.07 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: 25 mg/mL (51.71 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with sonication.
(Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0682 mL | 10.3410 mL | 20.6821 mL | |
| 5 mM | 0.4136 mL | 2.0682 mL | 4.1364 mL | |
| 10 mM | 0.2068 mL | 1.0341 mL | 2.0682 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
